Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. (UNCY) priced its initial public offering on Jul 14, 2021 at $5.00 per share, within its $5.00–$6.00 range, raising $25M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $72.5M. Roth Capital was lead-left underwriter. Sheppard Mullin advised the company and Schiff Hardin advised the underwriters.

Unicycive Therapeutics, Inc. is a biotechnology company with two kidney disease programs. Renazorb is for hyperphosphatemia in chronic kidney disease patients, and UNI 494 is for acute kidney injury; both were licensed from Spectrum Pharmaceuticals.

Status

IPO

Ticker

UNCY

Exchange

Nasdaq Capital Market

Priced

Jul 14, 2021

IPO price

$5.00

Price range

$5.00–$6.00

Raised

$25M

Market cap at IPO price

$72.5M

First filed

May 21, 2021

Underwriters

Roth Capital

Company counsel

Sheppard Mullin

Underwriters' counsel

Schiff Hardin

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.